View ValuationGilead Sciences 将来の成長Future 基準チェック /36Gilead Sciences利益と収益がそれぞれ年間8.6%と5.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に31.8% 8.3%なると予測されています。主要情報8.6%収益成長率8.29%EPS成長率Biotechs 収益成長0%収益成長率5.2%将来の株主資本利益率31.79%アナリストカバレッジGood最終更新日24 Apr 2026今後の成長に関する最新情報Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2026Feb 11+ 1 more updateGilead Sciences, Inc. Revises Earnings Guidance for the Year 2025Oct 31Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2025Feb 12すべての更新を表示Recent updatesGilead Sciences, Inc. Receives U.S. FDA Priority Review For Once-Daily HIV Treatment Bictegravir Plus LenacapavirMay 02Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of 77.2% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others.Apr 29Gilead Sciences, Inc. to Report Q1, 2026 Results on May 07, 2026Apr 23Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion.Apr 08Insufficient new directors Apr 02Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Ouro Medicines, Inc. from Keymed Biosciences Inc. (SEHK:2162) and others for $2.2 billion.Mar 24+ 1 more updateGilead Sciences, Inc., Annual General Meeting, Apr 30, 2026Mar 23Gilead Sciences, Inc. Announces the Presentation of New Phase 3 ARTISTRY-1 and ARTISTRY-2 Trial Data At CROI 2026Feb 26Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an agreement to acquire the remaining 88.50% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others for approximately $6.6 billion.Feb 23Gilead Sciences, Inc. to Present New Hiv Treatment and Prevention Data At Croi 2026, with A Focus on Expanding OptionsFeb 17Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2026Feb 11+ 1 more updateFda Approves Label Update for Kite's Yescarta®? for Relapsed/Refractory Primary Central Nervous System LymphomaFeb 06Gilead Sciences, Inc. to Report Q4, 2025 Results on Feb 10, 2026Jan 28Gilead Sciences, Inc. Announces New England Journal of Medicine Publishes Phase 3 ASCENT-04/KeyNOTE-D19 Results Supporting Trodelvy®? Plus Keytruda®? as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-Negative Breast CancerJan 22Insufficient new directors Dec 24Gilead Sciences, Inc. Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Effective December 18, 2025Dec 18Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ARTISTRY-2 TrialDec 15Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025Nov 20Gilead Sciences, Inc. Joins Partners for Delivery of First Shipments of Breakthrough Twice-Yearly Lenacapavir for HIV Prevention to Sub-Saharan AfricaNov 18Gilead Sciences, Inc.'s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ART-1 TrialNov 13Gilead Sciences, Inc. Provides Update on Phase 3 ASCENT-07 StudyNov 07+ 1 more updateGilead Sciences, Inc. announces Quarterly dividend, payable on December 30, 2025Nov 01Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2025Oct 31Gilead Sciences, Inc. to Showcase Interim Long-Term Efficacy Data for Livdelzi (Seladelpar) in Primary Biliary Cholangitis (Pbc) and Investigational Bulevirtide in Chronic Hepatitis DeltaOct 23Gilead Sciences, Inc. Receives Health Canada Approval for the Treatment of Primary Biliary CholangitisOct 22Gilead Sciences, Inc. to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025Oct 20+ 1 more updateGilead Presents New Hiv Research Data At EACS 2025 – Driving Scientific Innovation in Treatment and PreventionOct 16Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care with New Data At Esmo 2025Oct 14Gilead Sciences, Inc. to Report Q3, 2025 Results on Oct 30, 2025Oct 10Insufficient new directors Oct 02Upcoming dividend of US$0.79 per share Sep 10Insufficient new directors Sep 10Gilead Sciences, Inc. Announces European Commission Authorizes Twice-Y Early Yeytuo (Lenacapavir) for HIV PreventionAug 26Gilead Sciences, Inc. (NasdaqGS:GILD) announces an Equity Buyback for $6,000 million worth of its shares.Aug 08+ 2 more updatesGilead Receives Positive CHMP Opinions Under Accelerated Review from European Medicines Agency for Twice-Yearly HIV PrEP Option in the European UnionJul 25+ 1 more updateGilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention At Ias 2025Jul 14Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approves Yeztugo (Lanacapavir) as Pre-Exposure ProphylaxisJun 19Insufficient new directors Jun 17Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast CancerJun 01Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of TrodelvyMay 23Gilead's Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented At EASL 2025May 07+ 1 more updateGilead Sciences, Inc. to Present Latest Advancements Across Primary Biliary Cholangitis and Viral HepatitisApr 29Gilead Sciences, Inc. Declares Quarterly Dividend for the Second Quarter of 2025, Payable on June 27, 2025Apr 25+ 1 more updateGilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-04/KeyNOTE-D19 StudyApr 21Gilead Sciences, Inc. to Report Q1, 2025 Results on Apr 24, 2025Apr 11Gilead Sciences, Inc., Annual General Meeting, May 07, 2025Mar 28Gilead Sciences, Inc. Presents New HIV Treatment and Cure Research Data At CROI 2025, Including an Investigational Long-Acting, Twice-Y Early Therapy OptionMar 12+ 1 more updateEuropean Medicines Agency Validates Gilead's Marketing Authorization Application and Eu-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv PreventionFeb 25Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary CholangitisFeb 21Gilead Sciences, Inc. Announces U.S. FDA Acceptance of Its New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority ReviewFeb 18Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2025Feb 12Full year 2024 earnings released: EPS: US$0.39 (vs US$4.54 in FY 2023) Feb 12Gilead Sciences, Inc. Announces Increase in First Quarter 2025 Dividend, Payable on March 28, 2025Feb 12Insufficient new directors Jan 30Gilead Sciences, Inc. to Report Q4, 2024 Results on Feb 11, 2025Jan 29Insufficient new directors Dec 24Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary CholangitisDec 13+ 1 more updateKite, Gilead Company, Announces Results from Four Analyses That Continue to Demonstrate Durability of Response of Tecartus in Patients with R/R MCL and R/R B-ALL During 66th ASH Annual Meeting and ExpositionDec 10+ 1 more updateGilead Sciences, Inc.' Company Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASHDec 09Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 ResultsNov 28Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary CholangitisNov 16Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV GlasgowNov 13Third quarter dividend of US$0.77 announced Nov 09Third quarter 2024 earnings released: EPS: US$1.01 (vs US$1.75 in 3Q 2023) Nov 08Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024Nov 07Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48Oct 21Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024Oct 10+ 1 more updateGilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention ConferenceOct 07Upcoming dividend of US$0.77 per share Sep 06Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDAAug 15Second quarter 2024 earnings released: EPS: US$1.29 (vs US$0.84 in 2Q 2023) Aug 10Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024Jul 26Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025Jul 17Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in AsiaJun 27Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 TrialJun 21Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label StudyJun 08Upcoming dividend of US$0.77 per share Jun 07Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver DiseaseJun 06Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal CancerJun 05+ 2 more updatesGilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 StudyJun 01Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 StudyMay 31Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramMay 11First quarter dividend of US$0.77 announced May 06業績と収益の成長予測SNSE:GILD - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202833,78310,86713,50214,3002112/31/202732,05010,12013,26213,5142512/31/202630,2158,58212,68512,7392712/31/202529,4438,5109,45610,019N/A9/30/202529,0878,1109,1629,667N/A6/30/202528,8636,3119,3699,868N/A3/31/202528,7355,9659,84410,366N/A12/31/202428,75448010,30510,828N/A9/30/202428,2991269,43110,022N/A6/30/202427,8051,0546,8967,468N/A3/31/202427,4504857,9008,481N/A12/31/202327,1165,6657,4218,006N/A9/30/202327,3915,8767,8538,404N/A6/30/202327,3825,4848,9269,512N/A3/31/202327,0435,5838,3868,976N/A12/31/202227,2814,5928,3449,072N/A9/30/202227,1363,3349,0079,710N/A6/30/202227,5154,1379,41510,100N/A3/31/202227,4724,5159,95310,614N/A12/31/202127,3056,22510,80511,384N/A9/30/202127,4827,3949,49110,095N/A6/30/202126,6385,1628,4729,092N/A3/31/202125,5643018,6989,342N/A12/31/202024,6891237,5188,168N/A9/30/202023,1471,2688,1608,832N/A6/30/202022,174-2578,5109,227N/A3/31/202022,7164,9628,2449,003N/A12/31/201922,4495,3868,3199,144N/A9/30/201922,3652,693N/A8,909N/A6/30/201922,3575,955N/A8,476N/A3/31/201922,3205,892N/A7,707N/A12/31/201822,1275,455N/A8,400N/A9/30/201822,2811,587N/A8,808N/A6/30/201823,1972,208N/A9,290N/A3/31/201824,6903,464N/A11,243N/A12/31/201726,1074,628N/A11,898N/A9/30/201727,47811,601N/A12,684N/A6/30/201728,46612,213N/A14,383N/A3/31/201729,10112,637N/A15,842N/A12/31/201630,39013,501N/A17,047N/A9/30/201631,57615,076N/A18,382N/A6/30/201632,37116,346N/A18,085N/A3/31/201632,83917,341N/A18,758N/A12/31/201532,63918,108N/A21,250N/A9/30/201531,44716,912N/A18,476N/A6/30/201529,19415,043N/A18,424N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: GILDの予測収益成長率 (年間8.6% ) は 貯蓄率 ( 5.6% ) を上回っています。収益対市場: GILDの収益 ( 8.6% ) はCL市場 ( 4.3% ) よりも速いペースで成長すると予測されています。高成長収益: GILDの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: GILDの収益 ( 5.2% ) CL市場 ( 7.1% ) よりも低い成長が予測されています。高い収益成長: GILDの収益 ( 5.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: GILDの 自己資本利益率 は、3年後には高くなると予測されています ( 31.8 %)成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/02 20:34終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Gilead Sciences, Inc. 27 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。66 アナリスト機関David ToungArgus Research CompanyBrian SkorneyBairdEmily FieldBarclays63 その他のアナリストを表示
Gilead Sciences, Inc. Receives U.S. FDA Priority Review For Once-Daily HIV Treatment Bictegravir Plus LenacapavirMay 02
Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of 77.2% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others.Apr 29
Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion.Apr 08
Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Ouro Medicines, Inc. from Keymed Biosciences Inc. (SEHK:2162) and others for $2.2 billion.Mar 24+ 1 more update
Gilead Sciences, Inc. Announces the Presentation of New Phase 3 ARTISTRY-1 and ARTISTRY-2 Trial Data At CROI 2026Feb 26
Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an agreement to acquire the remaining 88.50% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others for approximately $6.6 billion.Feb 23
Gilead Sciences, Inc. to Present New Hiv Treatment and Prevention Data At Croi 2026, with A Focus on Expanding OptionsFeb 17
Fda Approves Label Update for Kite's Yescarta®? for Relapsed/Refractory Primary Central Nervous System LymphomaFeb 06
Gilead Sciences, Inc. Announces New England Journal of Medicine Publishes Phase 3 ASCENT-04/KeyNOTE-D19 Results Supporting Trodelvy®? Plus Keytruda®? as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-Negative Breast CancerJan 22
Gilead Sciences, Inc. Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Effective December 18, 2025Dec 18
Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025Nov 20
Gilead Sciences, Inc. Joins Partners for Delivery of First Shipments of Breakthrough Twice-Yearly Lenacapavir for HIV Prevention to Sub-Saharan AfricaNov 18
Gilead Sciences, Inc.'s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ART-1 TrialNov 13
Gilead Sciences, Inc. to Showcase Interim Long-Term Efficacy Data for Livdelzi (Seladelpar) in Primary Biliary Cholangitis (Pbc) and Investigational Bulevirtide in Chronic Hepatitis DeltaOct 23
Gilead Sciences, Inc. Receives Health Canada Approval for the Treatment of Primary Biliary CholangitisOct 22
Gilead Sciences, Inc. to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025Oct 20+ 1 more update
Gilead Presents New Hiv Research Data At EACS 2025 – Driving Scientific Innovation in Treatment and PreventionOct 16
Gilead Sciences, Inc. Announces European Commission Authorizes Twice-Y Early Yeytuo (Lenacapavir) for HIV PreventionAug 26
Gilead Sciences, Inc. (NasdaqGS:GILD) announces an Equity Buyback for $6,000 million worth of its shares.Aug 08+ 2 more updates
Gilead Receives Positive CHMP Opinions Under Accelerated Review from European Medicines Agency for Twice-Yearly HIV PrEP Option in the European UnionJul 25+ 1 more update
Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approves Yeztugo (Lanacapavir) as Pre-Exposure ProphylaxisJun 19
Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast CancerJun 01
Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of TrodelvyMay 23
Gilead's Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented At EASL 2025May 07+ 1 more update
Gilead Sciences, Inc. to Present Latest Advancements Across Primary Biliary Cholangitis and Viral HepatitisApr 29
Gilead Sciences, Inc. Declares Quarterly Dividend for the Second Quarter of 2025, Payable on June 27, 2025Apr 25+ 1 more update
Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-04/KeyNOTE-D19 StudyApr 21
Gilead Sciences, Inc. Presents New HIV Treatment and Cure Research Data At CROI 2025, Including an Investigational Long-Acting, Twice-Y Early Therapy OptionMar 12+ 1 more update
European Medicines Agency Validates Gilead's Marketing Authorization Application and Eu-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv PreventionFeb 25
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary CholangitisFeb 21
Gilead Sciences, Inc. Announces U.S. FDA Acceptance of Its New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority ReviewFeb 18
Gilead Sciences, Inc. Announces Increase in First Quarter 2025 Dividend, Payable on March 28, 2025Feb 12
Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary CholangitisDec 13+ 1 more update
Kite, Gilead Company, Announces Results from Four Analyses That Continue to Demonstrate Durability of Response of Tecartus in Patients with R/R MCL and R/R B-ALL During 66th ASH Annual Meeting and ExpositionDec 10+ 1 more update
Gilead Sciences, Inc.' Company Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASHDec 09
Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 ResultsNov 28
Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary CholangitisNov 16
Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV GlasgowNov 13
Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024Nov 07
Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48Oct 21
Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024Oct 10+ 1 more update
Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention ConferenceOct 07
Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDAAug 15
Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in AsiaJun 27
Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 TrialJun 21
Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver DiseaseJun 06
Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal CancerJun 05+ 2 more updates